Agomab Therapeutics has announced interim results from a Phase 1 study of AGMB-447 inhaled ALK5 inhibitor that was initiated in 2023. The data from the SAD/MAD portion of the study in 108 healthy participants found that AGMB-447 was generally safe and well tolerated and that systemic exposure was low, the company said. The final portion of the study, which is already underway, is investigating nebulized AGMB-447 delivered over a 14-day treatment period to patients with idiopathic pulmonary fibrosis.
In October 2024, Agomab announced that it had raised $89 million for development of several products, including AGMB-447. The company says that it plans to initiate a Phase 2 study of AGMB-447 in IPF patients this year.
Agomab Chief Medical Officer Philippe Wiesel commented, “We are very pleased with the Phase 1 results for AGMB-447 announced today. The data point to a generally favorable safety, tolerability, and PK profile of AGMB-447 and show proof-of-mechanism of TGFβ/ALK5 inhibition in the lungs of healthy participants.”
Read the Agomab Therapeutics press release
